Haemolytic uraemic syndrome (HUS) is a heterogeneous group of diseases that result in a
common pathology, thrombotic microangiopathy, which is classically characterised by the …

Overactivation of the complement alternative pathway drives the pathogenesis of primary
atypical hemolytic uremic syndrome (aHUS). Genetically‐determined or acquired …

The overall diagnostic yield of massively parallel sequencing–based tests in patients with
chronic kidney disease (CKD) is 30% for paediatric cases and 6–30% for adult cases. These …

Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic
haemolytic anaemia and end organ damage. TMAs have varying underlying …

The objective of this guideline is to provide healthcare professionals with clear, up‐to‐date
and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) …

Atypical hemolytic uremic syndrome (aHUS) is a rare disorder characterized by
dysregulation of the alternate pathway. The diagnosis of aHUS is one of exclusion, which …

Over a century after the discovery of the complement system, the first complement
therapeutic was approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) …

Thrombotic microangiopathy (TMA) is a rare and potentially life-threatening condition that
can be caused by a heterogeneous group of diseases, often affecting the brain and kidneys …

Historically, the majority of patients with complement-mediated atypical hemolytic uremic
syndrome (CaHUS) progress to end-stage kidney disease (ESKD). Single-arm trials of …

EKG wrote the article and contributed to data collection and analysis. KSJ contributed to the
drafting of the article and data collection. VB contributed to the drafting of the article and data …